Antithrombotic therapy in peripheral artery disease - Antiplatelet therapy, anticoagulants, both or none

Thrombosis and Haemostasis

Volumn 104, Issue 2, 2010, Pages 196-199

  Tangelder, Marco J D ^a   Van Hattum, Eline S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE;

ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; BLEEDING; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COMORBIDITY; DEATH; DISEASE COURSE; DRUG COST; DRUG EFFICACY; ENDARTERECTOMY; HAZARD RATIO; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INTERMITTENT CLAUDICATION; LEG REVASCULARIZATION; LIMB ISCHEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SHORT SURVEY; STATISTICAL SIGNIFICANCE; STENT; STROKE; THROMBOSIS PREVENTION; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTICOAGULANTS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PATIENT SELECTION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77955450533     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-02-0104     Document Type: Short Survey

References (43)

1. Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-392.
2. Stoffers HE, Rinkens PE, Kester AD, et al. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. Int J Epidemiol 1996; 25: 282-290.
3. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510-515.
4. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. J Am Med Assoc 2001; 286: 1317-1324.
5. Balkau B, Vray M, Eschwege E. Epidemiology of peripheral arterial disease. J Cardiovasc Pharmacol 1994; 23 (Suppl 3): S8-16.
6. Kannel WB, Skinner JJ, Jr., Schwartz MJ, et al. Intermittent claudication. Incidence in the Framingham Study. Circulation 1970; 41: 875-883.
7. Kennedy M, Solomon C, Manolio TA, et al. Risk factors for declining ankle-brachial index in men and women 65 years or older: the Cardiovascular Health Study. Arch Intern Med 2005; 165: 1896-1902.
8. Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999; 20: 344-353.
9. Selvin E, Marinopoulos S, Berkenblit G, et al. Metaanalysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431.
10. Safar ME, Priollet P, Luizy F, et al. Peripheral arterial disease and isolated systolic hypertension: the AT-TEST study. J Hum Hypertens 2009; 23: 182-187.
11. O'Hare AM, Vittinghoff E, Hsia J, et al. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol 2004; 15: 1046-1051.
12. O'Hare AM, Rodriguez RA, Bacchetti P. Low ankle-brachial index associated with rise in creatinine level over time: results from the atherosclerosis risk in communities study. Arch Intern Med 2005; 165: 1481-1485.
13. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J Am Med Assoc 2001; 285: 2481-2485.
14. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26: 517-538.
15. Dawson I, Sie RB, van der Wall EE, et al. Vascular morbidity and mortality during long-term followup in claudicants selected for peripheral bypass surgery. Eur J Vasc Endovasc Surg 1998; 16: 292-300.
16. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. J Am Med Assoc 2007; 297: 1197-1206.
17. Bennett PC, Silverman SH, Gill PS, et al. Peripheral arterial disease and Virchow's triad. Thromb Haemost 2009; 101: 1032-1040.
18. Blann AD, Tan KT, Tayebjee MH, et al. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 2005; 93: 578-583.
19. Rao AK, Vaidyula VR, Bagga S, et al. Effect of anti-platelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost 2006; 96: 738-743.
20. McDermott MM, Mehta S, Ahn H, et al. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997; 12: 209-215.
21. Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1989; 30: 50-57.
22. Hertzer NR. The natural history of peripheral vascular disease. Implications for its management. Circulation 1991; 83: I12-I19.
23. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl 1): S1-75.
24. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Anti-platelet Trialists' Collaboration. Br Med J 1994; 308: 81-106.
25. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
26. Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 815S-843S.
27. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
28. Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. J Am Med Assoc 2009; 301: 1909-1919.
29. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J 2008; 337: a1840.
30. Basili S, Raparelli V, Vestri A, et al. Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis. Thromb Haemost 2010; 103: 766-773.
31. Arfvidsson B, Lundgren F, Drott C, et al. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg 1990; 159: 556-560.
32. de Smit P, van Urk H. Dutch oral anticoagulation trial. Act Chir Austr 1992; 24: 5.
33. Kretschmer G, Herbst F, Prager M, et al. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 1992; 127: 1112-1115.
34. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Anti-platelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. Am Heart J 2006; 151: 1-9.
35. The Dutch BOA Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355: 346-351.
36. Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-227.
37. Budaj A, Eikelboom JW, Mehta SR, et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2009; 30: 655-661.
38. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
39. O'Donnell MJ, Kapral MK, Fang J, et al. Gastrointestinal bleeding after acute ischemic stroke. Neurology 2008; 71: 650-655.
40. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200-1206.
41. Segev A, Strauss BH, Tan M, et al. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J 2005; 150: 690-694.
42. Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 2007; 116: 2793-2801.
43. van Hattum ES, Algra A, Lawson JA, et al. Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation 2009; 120: 1569-1576.